Heron Therapeutics | HRTX - Net Income


Heron Therapeutics reported $-2.95M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
ALKERMES USD 501K 66.98M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amarin USD -1.22M 6.51M Dec/2025
ANI Pharmaceuticals USD 24.71M 4.78M Jun/2026
Anika Therapeutics USD 292K 2.62M Dec/2025
Arrowhead Research USD -194.28M 61.55M Jun/2026
Eisai JPY 18.24B 21.49B Jun/2026
Emergent BioSolutions USD -261.3M 78.3M Jun/2023
GlaxoSmithKline GBP 435M 1.3B Jun/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Insmed USD -13.24M 150.32M Jun/2026
Ligand Pharmaceuticals USD 48.51M 61.85M Jun/2026
Merck USD -1.34B 2.9B Jun/2026
Nektar Therapeutics USD -44.9M 8.82M Mar/2026
Neurocrine Biosciences USD 144.4M 53.5M Jun/2026
Omeros USD -32.23M 23.81M Sep/2024
Pacira USD 4.65M 1.74M Jun/2026
Regeneron Pharmaceuticals USD 1.3B 569.7M Jun/2026
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Veracyte USD 25.49M 3.22M Jun/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026